Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis

Table 3 Comparison of clinical and biochemical features according to stage of fibrosis (mean ± SD)

Features	No fibrosis	Fibrosis≥1	P
n (%)	28 (40.6)	41 (59.4)
Age (mo)	140.3 ± 34	151.4 ± 41	0.2
Fasting glucose (mg/dL)	82.4 ± 9.9	81.5 ± 11.7	0.7
BMI (kg/m2)	25.2 ± 3.3	27.5 ± 4.5	0.01
BMI-SDS	1.84 ± 0.5	2.0 ± 0.7	0.05
Cholesterol (mg/dL)	148.8 ± 34.4	160.2 ± 36.2	0.2
Triglycerides (mg/dL)	82.4 ± 59.5	97.9 ± 39.4	0.2
Systolic pressure (mmHg)	110.2 ± 11.6	116 ± 15	0.07
Diastolic pressure (mmHg)	67.0 ± 8.2	67.1 ± 8.3	0.9
AST (U/L)	41.6 ± 14.6	49.3 ± 32.2	0.18
ALT (U/L)	65.6 ± 26	76.2 ± 82.6	0.4
AST/ALT	0.7 ± 0.3	0.9 ± 0.5	0.05
GT (U/L)	25.2 ± 25	23.7 ± 16.6	0.7
PLT (103/L)	285 ± 66	295 ± 59	0.5
PT	87.9 ± 9.3	90.2 ± 7.6	0.3
HOMA-IR	2.7 ± 1.5	2.4 ± 1.1	0.4
ISI	4.0 ± 1.7	4.5 ± 1.9	0.4
Fasting insulin (mU/L)	13.5 ± 6.7	11.6 ± 5.8	0.2

BMI-SDS: body mass index standard deviation score; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PLT: platelets count; PT: prothrombin time; HOMA-IR: homeostatic model assessment-insulin resistence; ISI: insulin sensitivity index.